A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Official Title

An Open-Label, Multicentre, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma


This is a first-in-human, multi-centre clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or are non-amenable to SOC. This study will include an initial single participant dose-escalation part one followed by a multiple participant dose-escalation part two with the possibility of expansion.

Trial Description

Primary Outcome:

  • Percentage of Participants With Dose-Limiting Toxicities (DLTs)
  • Percentage of Participants with Adverse Events (AEs)
Secondary Outcome:
  • Maximum Concentration (Cmax) of RO7293583
  • Time of Maximum Concentration (Tmax) of RO7293583
  • Minimum Concentration (Cmin) of RO7293583
  • SC Bioavailability (F) of RO7293583
  • Clearance (CL) or Apparent Clearance (CL/F) of RO7293583
  • Volume of Distribution at Steady State (Vss) of RO7293583
  • Area Under the Curve (AUC) of RO7293583
  • Percentage of Participants with Anti-Drug Antibodies (ADAs) to RO7293583
  • Change from Baseline in RO7293583 ADA Titer
  • Objective Response Rate (ORR)
  • Disease Control Rate (DCR)
  • Duration of Response (DOR)
  • Progression-Free Survival (PFS)
  • Overall Survival (OS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society